The price differential between human and analogue insulins and the lack of significant differences in rates of serious hypoglycemia in recent reports have sparked new interest in the use of human insulin as a way to make health care more affordable to patients with diabetes.11,19 However, a recent meta-analysis20 and a recent World Health Organization position paper on diabetes care21,22 note that few methodologically rigorous studies have compared the relative effect of human vs analogue insulins on rates of major cardiovascular events and mortality in adults with type 2 diabetes. This evidence concerns the gene INS and Hypoglycemia.